Three-year Follow-up Study of Subjects Who Participated in a Previous Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052) Chronic Hepatitis C Clinical Trial

NCT ID: NCT01492504

Last Updated: 2019-11-27

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

1850 participants

Study Classification

OBSERVATIONAL

Study Start Date

2012-02-07

Study Completion Date

2018-03-19

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary purpose of this study is to determine whether the hepatitis C virus continues to remain unable to be detected in subjects who were previously treated with Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052) and achieved sustained virologic response.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hepatitis C

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Subjects with chronic hepatitis C

Subjects who participated in a clinical trial in which Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052) was administered for the treatment of chronic hepatitis C

Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052)

Intervention Type DRUG

Observational study - No Intervention \[(subjects were previously treated with Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052)\]

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052)

Observational study - No Intervention \[(subjects were previously treated with Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052)\]

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Signed Written Informed Consent
* Subjects must have received at least one dose of Asunaprevir and/or Daclatasvir
* Subjects participating in Daclatasvir and/or Asunaprevir studies (ie, protocol numbers beginning with AI443, AI444 or AI447) may enroll regardless of virologic response
* Completed the required post-treatment follow-up period in previous study
* Must enroll in this study within 6 months of completing previous BMS study or within 6 months of protocol availability at the clinical site
* Men and women, ages 18 and older

Exclusion Criteria

* Subject must not have been treated with any antiviral or immunomodulatory drug for chronic hepatitis C (CHC) after completion of the previous study during which Asunaprevir and/or Daclatasvir were administered
* Subject must not be participating in any other trial, excluding non-interventional trials
* Prisoners or subjects who are involuntarily incarcerated
* Subjects who are compulsorily detained for treatment of either a psychiatric or physical (eg, infectious disease) illness
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Bristol-Myers Squibb

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Bristol-Myers Squibb

Role: STUDY_DIRECTOR

Bristol-Myers Squibb

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Alabama Liver & Digestive Specialists (Alds)

Montgomery, Alabama, United States

Site Status

Pacific Oaks Medical Group

Beverly Hills, California, United States

Site Status

Southern California Research Center

Coronado, California, United States

Site Status

Scripps Clinic

La Jolla, California, United States

Site Status

Keck Medical Center of USC, HCC 1

Los Angeles, California, United States

Site Status

Peter J Ruane Md Inc

Los Angeles, California, United States

Site Status

Anthony M. Mills Md Inc

Los Angeles, California, United States

Site Status

Precision Research Institute, Llc

San Diego, California, United States

Site Status

Quest Clinical Research

San Diego, California, United States

Site Status

Medical Associates Research Group

San Diego, California, United States

Site Status

U.Cal.-San Francisco

San Francisco, California, United States

Site Status

University Of Colorado Denver & Hospital

Aurora, Colorado, United States

Site Status

Yale New Haven Hospital

New Haven, Connecticut, United States

Site Status

Schiff Center for Liver Diseases

Miami, Florida, United States

Site Status

University Of Miami School Of Medicine

Miami, Florida, United States

Site Status

Orlando Immunology Center

Orlando, Florida, United States

Site Status

Florida Hospital Transplant Center

Orlando, Florida, United States

Site Status

Gastrointestinal Specialists Of Georgia

Marietta, Georgia, United States

Site Status

Ruth M. Rothstein CORE Center

Chicago, Illinois, United States

Site Status

Indiana University

Indianapolis, Indiana, United States

Site Status

Mercy Medical Center

Baltimore, Maryland, United States

Site Status

Digestive Disease Associates, P.A.

Catonsville, Maryland, United States

Site Status

Johns Hopkins University

Lutherville, Maryland, United States

Site Status

The Research Institute

Springfield, Massachusetts, United States

Site Status

University Of Michigan

Ann Arbor, Michigan, United States

Site Status

Saint Louis University

St Louis, Missouri, United States

Site Status

Southwest Care Center

Santa Fe, New Mexico, United States

Site Status

Nyu Medical Center

Great Neck, New York, United States

Site Status

University Of North Carolina At Chapel Hill School Of Med

Chapel Hill, North Carolina, United States

Site Status

Carolinas Medical Center

Charlotte, North Carolina, United States

Site Status

Carolinas Center For Liver Disease

Statesville, North Carolina, United States

Site Status

Mayo Clinic Rochester

Tulsa, Oklahoma, United States

Site Status

Healthcare Research Consultants

Tulsa, Oklahoma, United States

Site Status

Oregon Health & Science University

Portland, Oregon, United States

Site Status

Lehigh Valley Health Network

Allentown, Pennsylvania, United States

Site Status

University Of Pennsylvania School Of Medicine

Philadelphia, Pennsylvania, United States

Site Status

Gastro One

Germantown, Tennessee, United States

Site Status

Nashville Medical Research Institute

Nashville, Tennessee, United States

Site Status

Texas Clinical Research Institute

Arlington, Texas, United States

Site Status

Baylor College Of Medicine

Houston, Texas, United States

Site Status

Liver Associates Of Texas

Houston, Texas, United States

Site Status

MEDVAMC

Houston, Texas, United States

Site Status

Alamo Medical Research

San Antonio, Texas, United States

Site Status

Lifetree Clinical Research

Salt Lake City, Utah, United States

Site Status

Metropolitan Research

Annandale, Virginia, United States

Site Status

Inova Fairfax Hospital

Falls Church, Virginia, United States

Site Status

Bon Secours St. Mary's Hospital of Richmond, Inc.

Richmond, Virginia, United States

Site Status

Mcguire Dvamc

Richmond, Virginia, United States

Site Status

Harborview Medical Center

Seattle, Washington, United States

Site Status

Ssm Health Dean Med Group

Madison, Wisconsin, United States

Site Status

Fundacion Cidea De Paraguay

Ciudad de Buenos Aires, Buenos Aires, Argentina

Site Status

Centro Oncologico Integral

Mar del Plata, Buenos Aires, Argentina

Site Status

Hospital Austral

Prov. Buenos Aires, Buenos Aires, Argentina

Site Status

Instituto Centralizado De Asistencia E Investigacion Clinica

Prov de Santa Fe, Santa Fe Province, Argentina

Site Status

Local Institution

Buenos Aires, , Argentina

Site Status

Hospital Italiano De Buenos Aires

Buenos Aires, , Argentina

Site Status

Local Institution

Camperdown, New South Wales, Australia

Site Status

Local Institution

Darlinghurst, New South Wales, Australia

Site Status

Local Institution

Darlinghurst Nsw, New South Wales, Australia

Site Status

Local Institution

Randwick, New South Wales, Australia

Site Status

Local Institution

Westmead, New South Wales, Australia

Site Status

Local Institution

Woollongabba, Queensland, Australia

Site Status

Local Institution

Adelaide, South Australia, Australia

Site Status

Local Institution

Clayton Vic, Victoria, Australia

Site Status

Local Institution

Melbourne, Victoria, Australia

Site Status

Local Institution

Porto Alegre, Rio Grande do Sul, Brazil

Site Status

Local Institution

Rio de Janeiro, , Brazil

Site Status

Local Institution

Rio de Janeiro, , Brazil

Site Status

Local Institution

São Paulo, , Brazil

Site Status

Local Institution

Calgary, Alberta, Canada

Site Status

Local Institution

Edmonton, Alberta, Canada

Site Status

Local Institution

Vancouver, British Columbia, Canada

Site Status

Local Institution

Vancouver, British Columbia, Canada

Site Status

Local Institution

Victoria, British Columbia, Canada

Site Status

Local Institution

Toronto, Ontario, Canada

Site Status

Toronto General Hospital

Toronto, Ontario, Canada

Site Status

Local Institution

Regina, Saskatchewan, Canada

Site Status

Local Institution

Hvidovre, , Denmark

Site Status

Local Institution

Odense, , Denmark

Site Status

Local Institution

Clichy, , France

Site Status

Local Institution

Créteil, , France

Site Status

Local Institution

La Roche-sur-Yon, , France

Site Status

Local Institution

Lille, , France

Site Status

Local Institution

Limoges, , France

Site Status

Local Institution

Lyon, , France

Site Status

Local Institution

Marseille, , France

Site Status

Local Institution

Montpellier, , France

Site Status

Local Institution

Nice, , France

Site Status

Local Institution

Paris, , France

Site Status

Local Institution

Paris, , France

Site Status

Local Institution

Paris, , France

Site Status

Local Institution

Pessac, , France

Site Status

Local Institution

Toulouse, , France

Site Status

Local Institution

Vandœuvre-lès-Nancy, , France

Site Status

Local Institution

Düsseldorf, , Germany

Site Status

Local Institution

Essen, , Germany

Site Status

Local Institution

Frankfurt, , Germany

Site Status

Local Institution

Hamburg, , Germany

Site Status

Local Institution

Hanover, , Germany

Site Status

Local Institution

Heidelberg, , Germany

Site Status

Local Institution

Mainz, , Germany

Site Status

Mater Misericordiae University Hospital

Dublin, Dublin, Ireland

Site Status

St. James'S Hospital

Dublin, Dublin, Ireland

Site Status

Local Institution

Brescia, , Italy

Site Status

Local Institution

Cisanello (pisa), , Italy

Site Status

Local Institution

Milan, , Italy

Site Status

Local Institution

Pavia, , Italy

Site Status

Local Institution

Torino, , Italy

Site Status

Local Institution

Viale Del Policlinico, 155, , Italy

Site Status

Local Institution

Nagoya, Aichi-ken, Japan

Site Status

Local Institution

Chiba, Chiba, Japan

Site Status

Local Institution

Fukuoka, Fukuoka, Japan

Site Status

Local Institution

Kurume, Fukuoka, Japan

Site Status

Local Institution

Ogaki-shi, Gifu, Japan

Site Status

Local Institution

Hiroshima, Hiroshima, Japan

Site Status

Local Institution

Sapporo, Hokkaido, Japan

Site Status

Local Institution

Amagasaki-shi, Hyōgo, Japan

Site Status

Local Institution

Kanazawa, Ishikawa-ken, Japan

Site Status

Local Institution

Takamatsu, Kagawa-ken, Japan

Site Status

Local Institution

Kagoshima, Kagoshima-ken, Japan

Site Status

Local Institution

Kawasaki-shi, Kanagawa, Japan

Site Status

Local Institution

Sendai, Miyagi, Japan

Site Status

Local Institution

Okayama, Okayama-ken, Japan

Site Status

Local Institution

Osaka, Osaka, Japan

Site Status

Local Institution

Osaka-sayama-shi, Osaka, Japan

Site Status

Local Institution

Suita, Osaka, Japan

Site Status

Local Institution

Suita-shi, Osaka, Japan

Site Status

Local Institution

Iruma-gun, Saitama, Japan

Site Status

Local Institution

Bunkyo-ku, Tokyo, Japan

Site Status

Local Institution

Minato-ku, Tokyo, Japan

Site Status

Local Institution

Musashino-shi, Tokyo, Japan

Site Status

Local Institution

Shinagawa-ku, Tokyo, Japan

Site Status

Local Institution

Chuo-shi, Yamanashi, Japan

Site Status

Local Institution

Guadalajara, Jalisco, Mexico

Site Status

Local Institution

Cuernavaca, Morelos, Mexico

Site Status

Local Institution

Monterrey, Nuevo León, Mexico

Site Status

Local Institution

Bialystok, , Poland

Site Status

Local Institution

San Juan, , Puerto Rico

Site Status

Local Institution

Yangsan, Gyeongsangnam-do, South Korea

Site Status

Local Institution

Busan, , South Korea

Site Status

Local Institution

Busan, , South Korea

Site Status

Local Institution

Busan, , South Korea

Site Status

Local Institution

Alicante, , Spain

Site Status

Local Institution

Barcelona, , Spain

Site Status

Local Institution

Barcelona, , Spain

Site Status

Local Institution

Madrid, , Spain

Site Status

Local Institution

Madrid, , Spain

Site Status

Local Institution

Madrid, , Spain

Site Status

Local Institution

Madrid, , Spain

Site Status

Local Institution

Málaga, , Spain

Site Status

Local Institution

Santiago de Compostela, , Spain

Site Status

Local Institution

Seville, , Spain

Site Status

Local Institution

Valencia, , Spain

Site Status

Local Institution

Gothenburg, , Sweden

Site Status

Local Institution

Stockholm, , Sweden

Site Status

Local Institution

Taichung, , Taiwan

Site Status

Kings College Hospital

London, Greater London, United Kingdom

Site Status

Local Institution

London, Greater London, United Kingdom

Site Status

Imperial College London

London, Greater London, United Kingdom

Site Status

North Manchester General Hospital

Manchester, Greater Manchester, United Kingdom

Site Status

Gartnaval General Hospital

Glasgow, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Argentina Australia Brazil Canada Denmark France Germany Ireland Italy Japan Mexico Poland Puerto Rico South Korea Spain Sweden Taiwan United Kingdom

References

Explore related publications, articles, or registry entries linked to this study.

Reddy KR, Pol S, Thuluvath PJ, Kumada H, Toyota J, Chayama K, Levin J, Lawitz EJ, Gadano A, Ghesquiere W, Gerken G, Brunetto MR, Peng CY, Silva M, Strasser SI, Heo J, McPhee F, Liu Z, Yang R, Linaberry M, Noviello S. Long-term follow-up of clinical trial patients treated for chronic HCV infection with daclatasvir-based regimens. Liver Int. 2018 May;38(5):821-833. doi: 10.1111/liv.13596. Epub 2017 Oct 12.

Reference Type DERIVED
PMID: 28941023 (View on PubMed)

Related Links

Access external resources that provide additional context or updates about the study.

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2011-005287-21

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

AI444-046

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.